Background To achieve yaws eradication, the use of the new WHO strategy of initial mass treatment with azithromycin and surveillance twice a year needs to be extended everywhere the disease occurs. However, the geographic scope of the disease is unknown. We aimed to synthesise published and unpublished work to update the reported number of people with yaws at national and subnational levels and to estimate at-risk populations.
Introduction
Yaws is a neglected tropical disease caused by Treponema pallidum subspecies pertenue. 1 This bacterium causes a chronic relapsing non-venereal treponematosis, characterised by highly contagious primary and secondary cutaneous lesions and non-contagious tertiary destructive lesions of the bones. The infection can become latent at any time, with only serological evidence of infection, and relapses can occur for up to 5-10 years. The ratio of clinically apparent to latent cases has been estimated to be as high as 1:6. 1 In 2012, WHO launched a new initiative to eradicate yaws by 2020.
2 Undertaking surveys and mapping the disease at a community level and immediately treating the entire endemic community with single-dose azithromycin 3 is recommended. 2 The effi cacy of this approach has been shown in a study of mass treatment in Papua New Guinea. 4 A key principle inherent in an eradication campaign is the need to intervene everywhere the disease occurs. However, the present geographic extent of yaws is incompletely known, because yaws is not a notifi able disease in many aff ected countries. To guide the WHO eradication programme, a better knowledge of yaws epidemiology is needed.
Data that can be used to identify the burden of yaws in a community include the prevalence of active infectious yaws (ie, ulcers or papilloma), which shows the intensity of yaws transmission, and the prevalence of latent yaws (ie, seropositivity in healthy individuals), which shows the extent of latent or hidden infection in the community. Clinical surveys for active yaws lesions can be done without any sophisticated laboratory test through interviews and physical examinations, whereas serological tests measuring yaws antibody (treponemal and non-treponemal) are needed for surveys of latent disease. 5 Another important source of information is national routine surveillance data, which allow estimation of the incidence of yaws at country and regional levels; countries report the number of cases at the fi rst administrative level.
In this study, we undertook a systematic review of published and unpublished work to improve our understanding of yaws epidemiology stratifi ed by country, and to provide an update on the number of people with active yaws to estimate at-risk populations in endemic countries.
Methods

Search strategy and selection criteria
We did a systematic review to identify all relevant studies that examined yaws prevalence and incidence. We searched PubMed and WHO databases for ("yaws" OR "treponematosis" AND "prevalence" OR "incidence") OR ("yaws" AND [each individual previous and current yaws-endemic country] 6 ). We consulted the Department for the Control of Neglected Tropical Diseases at WHO regarding previous and present yaws-endemic countries. 6 We limited the search to studies published between Jan 1, 1990, and Dec 31, 2014 . This period covers studies published since the last systematic review of yaws epidemiology, which was published in 1992. 7 No language restrictions were set for searches. We hand-searched the reference lists of all recovered documents for additional references. We also searched for ongoing or recently completed but unpublished studies from the WHO yaws surveillance network.
We included studies if they investigated active or latent yaws prevalence or incidence. Studies on active yaws had to meet the surveillance case defi nition provided by WHO:
8 a person with a history of residence in an aff ected area who presents with signs of clinically active yaws, consisting of chronic skin ulcers, multiple papillomata, squamous macules, bone or joint lesions, or plantar hyperkeratosis. For latent yaws seroprevalence studies, we deemed serological test rapid plasma reagin titres of at least 1:2 and venereal disease research laboratory titres of at least 1:2 as acceptable evidence of untreated latent infection. Use of the treponemal test (T pallidum haemagglutination assay, T pallidum particle agglutination assay, and the fl uorescent treponemal antibody absorption) alone was not suffi cient evidence of latent infection because people who have had yaws at any time will test positive for life, even after successful treatment.
Procedures
We calculated the number of people with active disease at the fi rst administrative level (eg, province, region, and prefecture) between Jan 1, 2010, and Dec 31, 2013. First, whenever possible, we obtained the country estimates of yaws cases at the fi rst administrative level from the latest national reporting fi gures provided to WHO. 6 Second, for countries for which no recent data were available, we contacted yaws control programme managers to request offi cial national routine surveillance data. To estimate the maximum population at risk of yaws, we made calculations at the second administrative level (eg, district, department, and regency). We contacted yaws control programme managers to request data on the proportion of second-administrative level regions that reported yaws cases in 2012. We summed the population living in endemic districts using the 2012 reported populations.
Statistical analysis
For all qualifying studies, we extracted data on study country, sample size, diagnostic test used, number of people with latent or active yaws, and age range. We undertook descriptive analyses of the extracted data. Prevalence estimates are presented for each study with 95% CIs on the basis of binomial distribution. We did not undertake quantitative meta-analyses because the studies we identifi ed did not sample populations at random and hence the estimates are not representative for a broader geographical area. All statistical analyses were done using Stata version 13.1.
Role of the funding source
There was no funding source for this study. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Our systematic review identifi ed 103 records, from which we identifi ed 23 eligible published articles that described 27 studies that met our inclusion criteria (fi gure 1). We included data from an additional four studies identifi ed from other sources (personal communications with country managers and yaws experts: Tabah EN, personal communication; Boua B, personal communication; Nsiire A, personal communication; Ayelo G, personal communication). The included studies covered 18 countries. Three of these countries-Guyana, Nigeria, and Wallis and Futunawere classifi ed by WHO as previously endemic countries with unknown status in 2012. Two countries-Ecuador and India-were reported to have eliminated yaws.
29,31
The remaining 13 countries were classifi ed as known endemic countries in 2012. 6 Among the 31 studies, 16 reported data on active yaws prevalence ( 14 and 2·95% in the Republic of Congo. 10 Overall, eight studies reported data on the prevalence of latent yaws (table 1; Ayelo G, personal communication). 9, [25] [26] [27] [28] [29] 31 After excluding one study from India 31 in which no seropositive cases were detected, prevalence of reactive serology ranged from 2·45% in Benin (Ayelo G, personal communication) to 31·05% in Tanna Island, Vanuatu. 26 Seroprevalence estimates were high in all three studies from the western Pacifi c region. [25] [26] [27] Other studies reporting high seroprevalence were done in Lobaye, Central African Republic (19·72%). 9 In Ecuador, after the implementation of a yaws surveillance and treatment programme, serological surveys done in 1998 showed a low prevalence of reactive serology (3·54%), 29 and a survey in India in 2005 reported no sero-reactors among 3821 children younger than 5 years. 31 Table 2 summarises health-facility-based incidence studies that used passive case fi nding. 11, 12, 15, 17, [21] [22] [23] In the study in Nigeria, the results for skin diseases were reported in 2001, mainly in adults, but no cases of yaws were noted. 17 Among the remaining studies, incidence of yaws ranged between 0·15 cases per 1000 populationyears in Côte d'Ivoire 11 to 25·56 per 1000 population-years in a highly endemic area of Papua New Guinea. 22 During the 4-year period between 2010 and 2013, 256 343 yaws cases were reported to WHO from 11 countries and territories (fi gure 2). Togo and TimorLeste are judged by WHO to be endemic, but did not report any case in the study period. Large-scale yaws control programmes have recently resulted in disease elimination in two countries (Ecuador and India). 29, 31 Figure 2 shows the annual number of yaws cases in all countries with ongoing transmission. The reported number of active infections was below 300 per year in Benin, Cameroon, Central African Republic, Republic of Congo, and Democratic Republic of the Congo, but data were probably under-reported from all of these countries. 215 308 (84%) of 256 343 cases reported to WHO were from three countries-Papua New Guinea, Solomon Islands, and Ghana. Table 3 summarises the estimates of the number of people at risk of yaws, stratifi ed by region. We estimated that, in 2012, 8944 8862 people were living in yawsendemic areas: about 46·7 million people in Africa, 35·8 million in southeast Asia, and 7·0 million in the western Pacifi c. At-risk population estimates for Ghana, Côte d'Ivoire, and Indonesia might be revised down because not all communities in each endemic district in these countries are endemic for yaws. Figure 3 shows the cumulative number of yaws cases from 2010 to 2013 in the WHO Africa region, shown by subnational regions. Six subnational regions in Ghana were very highly endemic (ie, >5000 cases within the 4-year reporting period), including the Eastern, Central, Volta, Western, Ashanti, and Brong-Ahafo regions. In Côte d'Ivoire, the regions of Fromager, Sud-Bandama, Haut-Sassandra, and Bas-Sassandra were highly endemic (ie, 1000-4999 cases within the 4-year reporting period). The East region in Cameroon, Likouala department in the Republic of Congo, and Lobaye prefecture in Central African Republic, which are close to one another, were all moderately endemic (ie, 100-999 cases within the 4-year reporting period). Data from Central African Republic were limited to surveys in two regions and the situation of the rest of the country remains to be investigated. Figure 4 shows the cumulative number of yaws cases in the WHO western Pacifi c and southeast Asia regions within the 4-year period, shown by subnational region. In Papua New Guinea, fi ve provinces were very highly endemic (>5000 cases)-New Ireland, West New Britain, East New Britain, Madang, and Autonomous Region of Bougainville provinces-whereas seven provinces were highly endemic (1000-4999 cases). The Western province in Solomon Islands, and Tafea province in Vanuatu were also very highly endemic. In Indonesia, most cases were found in the province of Nusa Tenggara Timur, where 13 084 cases were reported during the 4-year period. No recent surveillance data have been reported from TimorLeste, but the country is regarded as endemic according to WHO. 
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Discussion
Our data show that about 65 000 yaws cases per year occurred in 13 endemic countries and that in at least 19 countries the incidence of yaws is unknown; thus, there has been limited progress since the last systematic review on yaws epidemiology in 1992 (85 000 yaws cases in 33 endemic countries). 7 In 1953, Hackett 32 estimated there were 50-150 million cases of yaws in 90 countries. A substantial decrease in the prevalence of yaws was brought about by the implementation of mass treatment campaigns and subsequent surveillance activities in the 1950s and 1960s. In many countries, yaws control and surveillance activities stopped after 1970, with a subsequent resurgence of yaws, particularly in parts of west and central Africa and in southeast Asia. 7 Little activity to control the infection has been undertaken since 1990. The scarcity of political will, inadequate funding, and weaknesses in primary health-care systems in aff ected countries have been the biggest obstacles to the reduction of the burden of yaws in the past two decades.
The methods proposed for assessing yaws burden have not changed substantially since 1953; however, unlike in the previous review by Hackett, 32 who sent a questionnaire to all countries in Africa and carefully analysed the replies, or in the review by Meheus and Antal, 7 who compiled original data from country reports submitted to WHO, we also extracted and synthesised a large amount of data from published studies, and complemented this with data from grey literature.
An important fi nding of our work is that almost 85% of all infections occurred in three countries-Ghana, Papua New Guinea, and Solomon Islands. 6 The results of individual studies in these countries, which showed high prevalence and incidence rates, are consistent with integrated surveillance data. An overall low number of cases have been reported in national surveillance programmes in other countries in central Africa. 6 However, we have shown that focal indigenous populations (ie, Pygmies) in the Central African Republic, Cameroon, Republic of Congo, and Democratic Republic of the Congo are aff ected by yaws, with prevalence of active disease ranging between 3% and 11% (Boua B, personal communication). 9, 10, 14 The main risk factor for these groups, as for in other settings in which yaws is highly endemic, is the scarcity of access to health care and poor personal hygiene.
Among the 13 known endemic countries, we estimated that a maximum of about 89 million people were living in yaws-endemic areas. In view of the focal nature of the disease, the size of the population at risk, in particular in Ghana, Côte d'Ivoire, and Indonesia, is uncertain. This global estimate of at-risk individuals would probably be revised down if community-based surveys were used to guide the implementation of mass treatment.
The major limitation of our study is the weakness of routinely reported data. Yaws is not a notifi able disease and the use of national routine surveillance data is likely to result in an under estimation of the real number of cases because yaws predominantly occurs in rural communities with poor access to health facilities, whereas available data are primarily from health facilities. The limited reliability of clinical diagnoses of yaws and the recognition that other organisms can cause clinically similar skin lesions in yaws-endemic countries 33, 34 causes problems for clinical case reporting. The weakness of reported data shows the limitations of the present data and supports the need for surveys as per the WHO strategy.
We did not undertake a meta-analysis for several reasons. First, the studies that we included were primarily implemented in settings where yaws is endemic and no random sampling from a general population was done. Hence, the prevalence estimates are not representative of a given district, province, or an entire country. Second, the number of studies from each WHO region was limited. Third, the inclusion and diagnostic criteria varied markedly between studies, with both children and adults and both clinical and serological defi nitions of yaws included. These factors make direct comparison of the survey fi ndings diffi cult.
The results of this systematic review contribute to the epidemiological knowledge needed to guide the preliminary estimation of resources that are necessary for a successful eradication programme. The inability of several countries to undertake more active surveillance and surveys is a major obstacle to achieving the WHO 2020 eradication target. The weaknesses of routinely reported data shows the need to establish a strict and sensitive surveillance system similar to other eradication programmes (eg, for Guinea worm and poliovirus) in a way that enables regionalisation of cases to make the decision about which communities need mass treatment and other control interventions.
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